Navigating the uncharted—Progressive multifocal leukoencephalopathy in a child with NMOSD treated with rituximab.

The article focuses on the treatment of Aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD) in children, emphasizing the importance of prompt intervention and long-term immunosuppressive therapy. Rituximab, a monoclonal antibody targeting CD20-positive B cells, has shown promise in reducing relapse frequency and controlling disease activity in pediatric NMOSD, although its safety profile in children requires careful evaluation due to the risk of opportunistic infections like progressive multifocal leukoencephalopathy (PML). The article highlights the necessity for rigorous risk assessment, pre-treatment screening for the John Cunningham virus (JCV), and regular monitoring to detect PML early. It advocates for further research into pediatric-specific risk factors and treatment strategies that balance effective immunosuppression with safety, emphasizing a collaborative approach among various medical specialties to optimize care for affected children. [Extracted from the article]